A cancer treatment called tamoxifen, which previously showed promise in preclinical studies for the treatment of amyotrophic lateral sclerosis (ALS), provides only modest and short-lasting benefits to patients with the disease, a small Phase 1/2 clinical trial has found. According to the study’s researchers, larger studies and longer…

After gathering input from patients, researchers, and advocates, the U.S Food and Drug Administration (FDA) has released new guidance on the development of therapies for amyotrophic lateral sclerosis (ALS). Among its recommendations, it is advising more communication with companies early on in the product development process, access to…

Glaciers are known for their slow movement and the transformative change that they leave in their wake. Most move only a few centimeters a day. Yet they produce lakes, cliffs, moraines, valleys, mountain arêtes and horns, and pronounced landscape striations. Perhaps stem cell research…

MediciNova has launched the Phase 2b/3 clinical trial that will explore the potential of ibudilast (MN-166) in patients with amyotrophic lateral sclerosis (ALS). Pending the success of the trial, the collected data will support the submission of a new drug application and the approval of ibudilast…

RaDaR, the catchy new name for the U.S. government-run Rare Diseases Registry Program, aims to help patient advocacy groups with limited resources build their own disease registries. The site was developed by the National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of…

Biogen’s investigational therapy tofersen can significantly reduce toxic levels of SOD1 protein and may slow disability progression in people with familial amyotrophic lateral sclerosis (ALS) caused by SOD1 mutations, interim study results show. The positive data from a Phase 1/2 clinical trial support advancing the experimental compound into Phase 3 studies…

Greater knowledge about clinical trials and the importance of genetic testing, as well as increased access to expert care, are key needs for people with neuromuscular disease, including those with amyotrophic lateral sclerosis (ALS), according to a large survey. The ONEVoice survey included 3,362 respondents, 2,430 of…

ALS News Today brought you daily coverage of important discoveries, treatment developments, clinical trials, and other events dealing with amyotrophic lateral sclerosis (ALS) throughout 2018. As a reminder of what mattered most to you in 2018, here are the 10 most-read articles of last year with a brief description…

Exploratory analysis of data collected in the FORTITUDE-ALS and VITALITY-ALS trials sponsored by Cytokinetics provide new insights to enhance the design of future clinical trials in amyotrophic lateral sclerosis (ALS). These findings were discussed at the 29th International Symposium on ALS/MND in Glasgow, Scotland, in several poster…

Biogen has decided to exercise its option to acquire from Ionis Pharmaceuticals the exclusive rights to develop and commercialize BIIB067 as a potential treatment for amyotrophic lateral sclerosis (ALS). The decision to license the investigational therapy is covered under the terms of a collaborative agreement between the two companies…